Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?

Am J Transplant · 2017 · PMC5215533 · PMID 27223882

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Although a robust comparison of no induction, IL2RA and rATG is lacking, current data suggest that early steroid withdrawal is safe in patients receiving induction therapy with a maintenance regimen that includes a calcineurin inhibitor and MPA and that there is a clear trend toward higher effectiveness with rATG compared with IL2RA induction.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.